SCHEMBL169907

SCHEMBL169907

COCCN(Cc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)c(F)c4)c3s2)nc1)C(=O)OC(C)(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.58
MET P08581 17/20 0.58
MST1R Q04912 2/20 0.58
AXL P30530 2/20 0.58
FLT3 P36888 2/20 0.58
PLK4 O00444 1/20 0.58
MAP4K4 O95819 1/20 0.58
ABL1 P00519 1/20 0.58
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
LYN P07948 1/20 0.58
HCK P08631 1/20 0.58
PDGFRB P09619 1/20 0.58
BCR P11274 1/20 0.58
SRC P12931 1/20 0.58
ABL2 P42684 1/20 0.58
FRK P42685 1/20 0.58
SYK P43405 1/20 0.58
DDR1 Q08345 1/20 0.58
MERTK Q12866 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103919 0.92 MET (0.61) KDRMETMST1RAXLFLT3
SCHEMBL106729 0.89 MET (0.73) KDRMETMST1RAXLFLT3
SCHEMBL13608234 0.86 MST1R (0.60) KDRMETMST1RAXLFLT3
SCHEMBL104760 0.85 MET (0.78) KDRMETMST1RAXLFLT3
SCHEMBL16660526 0.84 MET (0.55) KDRMETMST1RAXLFLT3
SCHEMBL2533066 0.84 MET (0.73) KDRMETMST1RAXLFLT3
SCHEMBL171868 0.83 MST1R (0.57) KDRMETMST1RAXLFLT3
SCHEMBL171838 0.83 MET (0.58) KDRMETMST1RAXLFLT3
SCHEMBL2121003 0.81 MET (0.78) KDRMETMST1RAXLFLT3
SCHEMBL17993543 0.81 MST1R (0.65) KDRMETMST1RAXLFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426108-B1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC (CA) 2016-08-10 EP disclosed
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
EP-2426108-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MethylGene Inc. (CA) 2012-03-07 EP disclosed
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors Mirati Therapeutics, Inc. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286984-A1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors MAP3K19, MAP3K9, MAP4K2 KDR 526/4885MET 1062/4885MST1R 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.